Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1

作者: Joseph Schoepfer , Paul Manley , Pascal Furet , Andreas Marzinzik , Bahaa Salem

DOI:

关键词:

摘要: La presente invention concerne des composes de formule (I) : dans laquelle Y, Y 1 , R 2 3 et 4 sont definis le resume l'invention; capables d'inhiber l'activite BCR-ABL1 mutants celui-ci. L'invention en outre un procede pour la preparation l'invention, preparations pharmaceutiques comprenant tels procedes d'utilisation traitement cancers.

参考文章(38)
D. Fabbro, G. Fendrich, V. Guez, T. Meyer, P. Furet, J. Mestan, J. D. Griffin, P. W. Manley, S. W. Cowan-Jacob, Targeted Therapy with Imatinib: An Exception or a Rule? Inhibitors of Protein Kinases and Protein Phosphates. ,vol. 167, pp. 361- 389 ,(2005) , 10.1007/3-540-26670-4_13
R. R. C. New, Liposomes : a practical approach IRL Press : Oxford University Press. ,(1990)
Jean Jacques, André Collet, Samuel H. Wilen, Enantiomers, Racemates, and Resolutions ,(1981)
Marco Genua, Giuseppe Pandini, Maria Francesca Cassarino, Rosa Linda Messina, Francesco Frasca, c-Abl and insulin receptor signalling. Vitamins and Hormones Series. ,vol. 80, pp. 77- 105 ,(2009) , 10.1016/S0083-6729(08)00604-3
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
Jose F Leis, Daniel E Stepan, Peter T Curtin, John M Ford, Bin Peng, Susan Schubach, Brian J Druker, Richard T Maziarz, Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) Leukemia & Lymphoma. ,vol. 45, pp. 695- 698 ,(2004) , 10.1080/10428190310001625728
Alessia P. M. Barbagallo, Richard Weldon, Robert Tamayev, Dawang Zhou, Luca Giliberto, Oded Foreman, Luciano D'Adamio, Tyr682 in the Intracellular Domain of APP Regulates Amyloidogenic APP Processing In Vivo PLoS ONE. ,vol. 5, pp. e15503- ,(2010) , 10.1371/JOURNAL.PONE.0015503